Investigating a new cancer therapy using translation initiation inhibitors
Translation Initiation Inhibitor for Cancer Therapy
This study is looking at how a substance called Interleukin-24 (IL-24) can help kill cancer cells and shrink tumors while being gentle on healthy cells, with the goal of creating a new treatment for solid tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Herbert H. Lehman College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11080969 on NIH RePORTER |
What this research studies
This research focuses on understanding how inhibiting translation initiation can lead to cancer cell death and tumor suppression through the action of Interleukin-24 (IL-24). By exploring the cellular mechanisms involved, the study aims to develop a targeted cancer therapy that minimizes harm to normal cells while effectively combating tumors. The approach includes both laboratory studies and in vivo testing to assess the safety and efficacy of IL-24 as a potential treatment for solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who are seeking new treatment options.
Not a fit: Patients with non-solid tumors or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel cancer therapy that is more effective and has fewer side effects than current treatments.
How similar studies have performed: Previous clinical testing of IL-24 has shown promising results, indicating that this approach has potential based on earlier successes.
Where this research is happening
New York, United States
- Herbert H. Lehman College — New York, United States (Active)
Researchers
- Principal investigator: Sauane, Moira — Herbert H. Lehman College
- Study coordinator: Sauane, Moira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.